The $3.70 price target has emerged as the most closely watched objective for SXTP after Ascendiant Capital Markets analyst Lucas Ward maintained a Buy rating while lowering his target from $4.20 to $3.70 in May 2026. With the stock trading in the $1.15 to $1.23 range, the implied upside exceeds 200% — a figure that naturally captures attention in the speculative biotech community. This target represents the only active published price objective from a major Wall Street firm after H.C. Wainwright removed its own target when downgrading the stock to Neutral the same month.
60 Degrees Pharmaceuticals, Inc., founded in 2010 and headquartered in Washington, D.C., is a specialty pharmaceutical company focused on developing and commercializing therapies for the prevention and treatment of infectious diseases. The company's flagship product, ARAKODA (tafenoquine), received U.S. Food and Drug Administration approval in 2018 for malaria prevention and is commercially available in both the United States and Australia. The pipeline includes tafenoquine under investigation for babesiosis, fungal infections, and other indications, as well as Celgosivir — a glucosidase inhibitor targeting Zika, respiratory viruses, and dengue fever. The company is also developing Australian Chestnut Extract as a botanical dietary supplement for over-the-counter applications.
SXTP trades as a micro-cap stock with a market capitalization of approximately $3 million to $4 million, placing it among the smallest publicly traded biotech companies. The stock executed a 1-for-4 reverse stock split in January 2026 to regain compliance with Nasdaq's minimum bid price requirement, a move that underscores ongoing listing concerns. Annual revenues stand at roughly $1.4 million, and the company continues to report net losses, including a first-quarter 2026 net loss of approximately $2.21 million. The stock has declined more than 78% over the trailing twelve months, reflecting deep investor skepticism about the commercial trajectory.
Several factors could potentially support a move toward the $3.70 analyst target. The company's babesiosis clinical trial is enrolling patients ahead of schedule, with interim analysis data expected as soon as mid-2026. Positive efficacy results could transform the investment narrative around tafenoquine's broader utility beyond malaria. Additionally, the GoodRx partnership announced in early 2026 may expand patient access to ARAKODA at over 70,000 pharmacies nationwide, potentially improving prescription volumes. The licensing agreement with Florida State University for castanospermine extraction also opens a potential revenue stream in the dietary supplement market. Any meaningful commercial breakthrough — combined with the stock's deeply depressed valuation — could generate outsized percentage gains given the tiny float and micro-cap structure.
The obstacles facing SXTP are substantial. H.C. Wainwright downgraded the stock to Neutral in May 2026, specifically citing Arakoda's disappointing revenue trajectory and what the firm described as an "increasingly untenable" spending position. The company's cash burn rate — with quarterly operating expenses exceeding $2 million against quarterly product revenues of approximately $162,000 — creates persistent dilution risk. A $1 million private placement priced at $1.74 per share in July 2026 highlights the company's ongoing need for external financing at prices that pressure existing shareholders. The reverse stock split, while addressing Nasdaq listing requirements, also signals the severity of the stock's decline. Without a clear path to profitability or a transformative clinical catalyst, the $3.70 target appears distant.
Analyst sentiment on SXTP has deteriorated markedly over the past year. Ascendiant Capital Markets remains the lone bull with a $3.70 target and Buy rating, though the firm has repeatedly lowered its target — from $28.00 in mid-2025 to $12.00, then $11.20, then $4.20, and finally $3.70. H.C. Wainwright downgraded the stock to Neutral in May 2026 and removed its price target entirely, while Weiss Ratings maintains a Sell (E+) rating. The consensus rating across four analysts now sits at Hold, with the average price target of $13.85 distorted by stale, outdated forecasts that no longer reflect current market conditions. The $3.70 target from Ascendiant is the only active, recently updated price objective that investors can reference.
From a technical perspective, SXTP trades in deeply bearish territory. The stock sits well below its 50-day moving average of approximately $1.52 and far beneath its 200-day moving average near $2.71. The 52-week range spans from $1.05 on the low end to $8.62 on the high end, illustrating the magnitude of the decline. The $1.74 level — where the recent private placement was priced — represents a near-term resistance zone that the stock must reclaim before any sustained recovery can develop. The $3.70 analyst target aligns loosely with a level the stock briefly traded near in December 2025 before the post-reverse-split decline accelerated. For SXTP to reach $3.70, it would first need to establish support above $1.50, then break through resistance at $2.00 and $2.70 — each representing significant overhead supply from prior trading ranges.
Traders tracking volatile micro-cap stocks like 60 Degrees Pharmaceuticals may benefit from tools that process large volumes of market data in real time. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-driven analysis. These signals are designed to help traders identify emerging opportunities, monitor existing positions, and detect shifts in market trends more efficiently than manual screening alone. For a stock as thinly traded and volatile as SXTP, staying ahead of rapid sentiment changes can be critical. Explore Tickeron's AI-powered tools to see how automated signal generation may complement your market research process.
The path to $3.70 for 60 Degrees Pharmaceuticals stock is theoretically possible but demands a convergence of highly favorable outcomes that currently appear unlikely based on available evidence. The strongest argument for reaching this level rests on the possibility of positive clinical data from the babesiosis trial or an unexpected commercial inflection in ARAKODA sales. However, the primary risks — persistent cash burn, ongoing dilution, a recent analyst downgrade, declining revenue, and a history of repeatedly lowered price targets — present formidable barriers. Investors should monitor clinical trial readouts, quarterly revenue trends, financing activity, and any changes in analyst coverage as the most relevant indicators of whether the $3.70 target can realistically be achieved. In the absence of a transformative catalyst, the stock faces an uphill battle to regain levels it last traded at many months ago.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that SXTP and ACXP have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SXTP and ACXP's prices will move in lockstep.
| Ticker / NAME | Correlation To SXTP | 1D Price Change % | ||
|---|---|---|---|---|
| SXTP | 100% | N/A | ||
| ACXP - SXTP | 29% Poorly correlated | +1.38% | ||
| OCGN - SXTP | 29% Poorly correlated | N/A | ||
| KROS - SXTP | 26% Poorly correlated | +0.73% | ||
| CABA - SXTP | 26% Poorly correlated | -1.88% | ||
| ADAG - SXTP | 25% Poorly correlated | -1.71% | ||
More | ||||